Clinical Trial Update: BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BAY 56-3722 for recurrent, unresectable, or metastatic renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• BAY 56-3722

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer | Phase 2 | Status: WITHDRAWN